Forsante Oy

Forsante Oy develops clinical decision-support tools and in vitro diagnostic (IVD) devices. Its products include the Prostate Cancer Advisor, which assists in prostate cancer diagnostics, and the Warfarin Advisor, designed to support anticoagulation management. Additionally, the company produces the IRMA system, a laboratory-based IVD device used for medical analysis. These tools are designed to automate treatment processes, improve care quality, and enhance patient outcomes.

Forsante Oy is based in Finland, operating within the European Union’s regulatory framework. Since its devices are classified under EU regulations, they must comply with applicable directives and standards, such as those governing medical devices and IVDs. This ensures alignment with EU requirements for safety, performance, and market placement.

Forsante Oy’s devices are listed in the eudamed database, which is the EU’s central registry for medical devices and IVDs. This registry is maintained under EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) requirements, ensuring transparency and traceability of devices marketed within the EU.

Forsante Oy’s devices fall under Class IIb medical device classification and the IVD General category for in vitro diagnostics. This classification is determined based on risk assessment criteria under EU regulations, where Class IIb devices pose moderate risks requiring additional scrutiny, and IVD General devices are considered low to moderate risk but still require regulatory oversight to ensure accuracy and safety.